News - Tradjenta


Current filters:


Popular Filters

Type 2 diabetes market to reach $38.8 billion by 2019


The global type 2 diabetes market is expected to expand from $20.4 billion in 2012 to $38.8 billion by…

Boehringer IngelheimDiabetesEli LillyEuropeGemigliptinMarkets & MarketingNesinaNorth AmericaPharmaceuticalTakeda PharmaceuticalsTradjenta

Positive Ph III data for Trajenta in elderly type 2 diabetes patients


Elderly people with type 2 diabetes (T2D) treated for 24 weeks with the dipeptidyl peptidase-4 (DPP-4)…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

FDA approves Boehringer and Lilly's Tradjenta and Jentadueto labeling to reflect pancreatitis risk


German family-owned Boehringer Ingelheim and US partner Eli Lilly (NYSE: LLY) revealed yesterday (June…

Boehringer IngelheimDiabetesEli LillyJentaduetoNorth AmericaPharmaceuticalRegulationTradjenta

FDA approves expanded use of Boehringer and Lilly's Tradjenta


German family-owned drug major Boehringer Ingelheim and US partner and Eli Lilly (NYSE: LLY) said on…

Boehringer IngelheimDiabetesEli LillyNorth AmericaPharmaceuticalRegulationTradjenta

Highlights of American Diabetes Association meeting


The weekend saw a flood of new data on diabetes drug candidates and currently approved treatments presented…

Boehringer IngelheimDegludecDiabetesEli LillyempagliflozinLyxumiaNovo NordiskPharmaceuticalResearchSanofiTradjentaVictoza

Boehringer/Lilly’s linagliptin demonstrates durable efficacy over two years


Results of a 102 week Phase III study for linagliptin (trade named Trajenta in Europe and Tradjenta in…

Boehringer IngelheimDiabetesEli LillyPharmaceuticalResearchTradjentaTrajenta

Boehringer and Lilly’s Trajenta approved for type 2 diabetes in Europe


Following a positive European Medicines Agency advisory committee recommendation two is months ago, Independent…

Boehringer IngelheimDiabetesEli LillyEuropePharmaceuticalRegulationTradjentaTrajenta

Boehringer Ingelheim and Lilly begin US roll-out of diabetes drug Tradjenta


German independent drug major Boehringer Ingelheim and USA-based Eli Lilly (NYSE: LLY) announced yesterday…

Boehringer IngelheimDiabetesEli LillyMarkets & MarketingNorth AmericaPharmaceuticalTradjenta

Amylin wins first round in squabble with Lilly over diabetes link with Boehringer


In an initial win for US biotech firm Amylin Pharmaceuticals (Nasdaq: AMLN), the US District Court for…

AmylinBoehringer IngelheimDiabetesEli LillyExenatide InjectionLegallinagliptinNorth AmericaPharmaceuticalTradjenta

Amylin sues Eli Lilly, alleging anti-competitive activity


San Diego, USA-based Amylin Pharmaceuticals (Nasdaq: AMLN) has filed a law suit against drug major Eli…

AmylinBoehringer IngelheimByettaDiabetesEli LillyLegallinagliptinPharmaceuticalTradjenta

US FDA clears Boehringer and Lilly’s diabetes drug Tradjenta


The US Food and Drug Administration has approved Tradjenta (linagliptin), for use along with diet and…

Boehringer IngelheimDiabetesEli LillylinagliptinNorth AmericaPharmaceuticalRegulationTradjenta

Company Spotlight



Back to top